
Stimulating insulin secretion from the pancreas when glucose levels are elevated
Inhibiting glucagon release, preventing the liver from producing excess glucose
Slowing gastric emptying, which results in prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists lower blood sugar by stimulating insulin secretion and inhibiting excess glucose production. These medications are commonly used when oral diabetes drugs like metformin do not sufficiently control blood sugar. Additionally, certain GLP-1 agonists have been shown to help reduce the risk of cardiovascular problems in people with type 2 diabetes and heart disease.
GLP-1 agonists like Wegovy and Saxenda are FDA-approved for weight loss in people without diabetes. These medications reduce hunger and increase feelings of fullness, making it easier for individuals to eat fewer calories. Clinical trials have demonstrated that combining GLP-1 therapy with healthy lifestyle changes can lead to significant, long-term weight loss.
GLP-1 receptor agonists help regulate blood sugar by enhancing insulin secretion and decreasing glucagon production, particularly after meals. This dual mechanism reduces post-meal blood sugar spikes and improves overall glycemic control. Since this effect is glucose-dependent, the risk of hypoglycemia is much lower than with many traditional diabetes medications, offering safer blood sugar management.
A major benefit of GLP-1 therapy is its role in promoting sustainable weight loss. By slowing gastric emptying and signaling to the brain that the body is full, GLP-1 medications help reduce hunger and make it easier to eat fewer calories. Clinical trials show that liraglutide, semaglutide, and tirzepatide lead to significant weight loss, which is often maintained with the addition of healthy lifestyle changes.



GLP-1/GIP co-agonists work by activating both GLP-1 and GIP receptors, offering a more effective way to regulate insulin and control appetite. This dual mechanism holds great potential for better managing conditions like diabetes and obesity.
By targeting both GLP-1 and glucagon receptors, GLP-1/glucagon co-agonists aim to improve weight loss and support energy metabolism while preserving muscle mass.

